Conatus Pharmaceuticals (NASDAQ: CNAT) reported Q2 EPS of ($0.31), $0.03 better than the analyst estimate of ($0.34).

For earnings history and earnings-related data on Conatus Pharmaceuticals (CNAT) click here.